1 documents found
Information × Registration Number 0213U004840, 0110U005758 , R & D reports Title Cationic antimicrobial peptides: expression patterns in melanoma cells in vitro and in vivo popup.stage_title Head Pogrebnoy Petro Vasylievich, Registration Date 30-12-2013 Organization R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology popup.description2 The cloning of genes coding for human beta-defensin-3 (hBD-3) and human beta-defensin-1(hBD-1) in bacterial cells using GST-system for production of recombinat proteins, has been perormed. Recombinant hBD-3 has been expressed and purified, and its biologic activity has been studied. It has been shown that rec-hBD-3 is active against B.subtilis and P.aeruginosa, but, unlike to hBD-2 and hBD-4, in nanomolar concentrations rec-hBD-3 has no effect on proliferation and viability of tumor cells of А431, А549 and ТРС-1 lines, doesn't stimulate melanin synthesis in human melanoma cells of MelZ and MlIs lines, and has no effect on morphology of tumor cells and their migration ability in vitro. Rec-hBD-3 enhances cytotoxic effect of other agents, in particular, docetaxel, rec-hBD-2 and rec-hBD-4 in vitro. Also, new data on biologic activity of rec-hBD-4 have been presented: at concentration of 1-100 нМ rec-hBD-4 stimulates cell cycle progression in G2/M checkpoint, potentiates colony-forming activity of tumor cells and their migration ability, while at higher concentrations (>500 нМ) rec-hBD-4 suppresses B-Raf expression, causes cell cycle arrest in G1/S checkpoint, inhibits migration ability of tumor cells and their colony-forming activity in semisoft medium. Product Description popup.authors Геращенко О.Л. Глушко Н.В. Журавель О.В Солдаткіна М.О. popup.nrat_date 2020-04-02 Close
R & D report
Head: Pogrebnoy Petro Vasylievich. Cationic antimicrobial peptides: expression patterns in melanoma cells in vitro and in vivo. (popup.stage: ). R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology. № 0213U004840
1 documents found

Updated: 2026-03-16